Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02610127 · ClinicalTrials.gov registry record
Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
A clinical trial, sponsored by Baxalta now part of Shire.
- Completed
- Registry status
- 53
- Enrollment target
NCT02610127 is a clinical trial that has completed, run by Baxalta now part of Shire. The registered enrollment target is 53 participants.
The verdict
NCT02610127 has completed, sponsored by Baxalta now part of Shire.
- COMPLETED
- Registry status
- 53 participants
- Enrollment target
Study Summary
The overall objective is to enroll patients with acquired hemophilia A (AHA) who are prescribed and treated with Obizur, to assess safety, and to describe factors related to safety, utilization and effectiveness in a real-world setting.
Interventions
- BIOLOGICAL OBIZUR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2015-12-30 |
| Est. Completion | 2019-06-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02610127
The ClinicalTrials.gov registry entry for NCT02610127 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baxalta now part of Shire, which has 74 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OBIZUR is the first listed.
NCT02610127 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02610127 about?
NCT02610127 is a clinical study titled "Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A". The overall objective is to enroll patients with acquired hemophilia A (AHA) who are prescribed and treated with Obizur, to assess safety, and to describe factors related to safety, utilization and effectiveness in a real-world setting.
What is the current status of trial NCT02610127?
This trial is currently completed. The enrollment target is 53 participants. The study started on 2015-12-30. Estimated completion is 2019-06-07.
What interventions are being tested in trial NCT02610127?
The interventions under investigation include: OBIZUR (BIOLOGICAL).
Who is sponsoring clinical trial NCT02610127?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.